Korea's Celltrion In Deal With U.S.-based Hospira For Biogeneric Sales; M&A Hinted At

SEOUL - South Korea's Celltrion inked an agreement with U.S.-based Hospira to collaborate on manufacturing and marketing Celltrion's eight biogeneric products in global markets including the U.S. and Europe

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip